Drug intelligence / Profile preview

SVT-22471

Development stage: Preclinical
Lead developer: Laboratorios Salvat
Modality: Small Molecules
Administration: Ophthalmic

Overview

**SVT-22471** is a Laboratorios Salvat ophthalmic fixed-dose combination in development for glaucoma. It combines an unspecified prostaglandin analogue with an unspecified beta-blocker and is being developed as a preservative-free, single-dose ophthalmic solution. The two pharmacologic components are intended to lower intraocular pressure through complementary mechanisms: prostaglandin analogues increase aqueous-humor outflow, while beta-blockers reduce aqueous-humor production.

Targets

ADRB1 (β1)PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on SVT-22471.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVT-22471.

Explore the full profile